E
Eloxx Pharmaceuticals, Inc.
ELOXCIK 0001035354NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31
Period
FY 2025
Revenue
$0
Net Income
$-6.00M
Total Assets
$5.27M
Equity
$-11.91M
Shares Out
7.57M
Op. Cash Flow
$-6.33M
Business
Eloxx Pharmaceuticals, Inc. is a publicly listed company in Biological Products, (No Diagnostic Substances), incorporated in Delaware. Common stock trades on Nasdaq under the ticker ELOX.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| License and service revenue: | 0 | 6 | 0 | — | — | |
| Research and development | 3 | 4 | 9 | 24 | 23 | |
| General and administrative | 3 | 5 | 9 | 11 | 20 | |
| Total operating expenses | 6 | 9 | 17 | 34 | 66 | |
| Loss from operations | −6 | −2 | −17 | −34 | −66 | |
| Other (income) expense, net | −443,000 | 675,000 | −234,000 | 2 | 709,000 | |
| Net loss | −6 | −3 | −17 | −36 | −67 | |
| Net loss per share, basic | −0.49 | −0.84 | −6.63 | −16.65 | −38.15 | |
| Net loss per share, diluted | −0.49 | −0.84 | −6.63 | −16.65 | −38.15 | |
| Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, basic | 12 | 4 | 3 | 2 | 2 | |
| Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, diluted | 12 | 4 | 3 | 2 | 2 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 100,000 | 1 | 19 | 42 | |
| Restricted cash | 6,000 | 5,000 | 220,000 | 261,000 | 299,000 | |
| License and service receivable | 0 | 2 | 0 | — | — | |
| Unbilled receivable | 0 | 359,000 | 0 | — | — | |
| Prepaid expenses and other current assets | 479,000 | 142,000 | 194,000 | 661,000 | 913,000 | |
| Total current assets | 5 | 3 | 2 | 20 | 43 | |
| Property and equipment, net | 0 | 0 | 35,000 | 169,000 | 216,000 | |
| Operating lease right-of-use asset | 0 | 0 | 129,000 | 825,000 | 1 | |
| Total assets | 5 | 3 | 2 | 21 | 45 | |
| Accounts payable | 3 | 5 | 6 | 3 | 1 | |
| Accrued expenses | 2 | 1 | 1 | 3 | 4 | |
| Current portion of long-term debt, net of unamortized debt discounts | 1 | 7 | 2 | 4 | 0 | |
| Accrued interest on debt | 35,000 | 557,000 | 48,000 | — | — | |
| Advances from collaboration partners | 12 | 13 | 13 | — | — | |
| Warrant liabilities | 0 | 0 | 376,000 | — | — | |
| Current portion of operating lease liability | 0 | 4,000 | 133,000 | 712,000 | 657,000 | |
| Derivative liabilities | 0 | 95,000 | 95,000 | 45,000 | 0 | |
| Total current liabilities | 17 | 27 | 23 | 23 | 10 | |
| Long-term debt, net of current portion | 0 | 0 | 2 | 9 | 12 | |
| Operating lease liability | 0 | 0 | 2,000 | 135,000 | 804,000 | |
| Total liabilities | 17 | 27 | 24 | 32 | 23 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued or outstanding as of December 31, 2025, 2024 and 2023 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.01 par value per share, 500,000,000 shares authorized, 4,617,739, 3,304,250 and 3,143,390 shares issued and outstanding as of December 31, 2025, 2024 and 2023, respectively | 48,000 | 35,000 | 31,000 | 22,000 | 22,000 | |
| Additional paid-in capital | 289 | 270 | 269 | 264 | 263 | |
| Accumulated deficit | −301 | −295 | −291 | −274 | −238 | |
| Total stockholders equity | −12 | −24 | −23 | −11 | 22 | |
| Total liabilities and stockholders equity | 5 | 3 | 2 | 21 | 45 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −6 | −3 | −17 | −36 | −67 | |
| Stock-based compensation | 235,000 | 541,000 | 2 | 3 | 9 | |
| Depreciation | 0 | 35,000 | 113,000 | 77,000 | 114,000 | |
| Amortization of operating lease right-of-use asset | 0 | 129,000 | 696,000 | 618,000 | 846,000 | |
| Amortization of debt discount | 245,000 | 468,000 | 259,000 | 541,000 | 420,000 | |
| Increase in fair value of derivative liabilities | 0 | 0 | 50,000 | 45,000 | 0 | |
| Imputed interest expense on 2025 bridge loans | 154,000 | 0 | 0 | — | — | |
| Change in fair value of warrant liabilities | 0 | −376,000 | −2 | — | — | |
| Extinguishment of the 2021 Award | −1 | 0 | 0 | — | — | |
| Write-off of fair value of derivative liabilities | −95,000 | 0 | 0 | — | — | |
| Loss on extinguishment of debt | 0 | 25,000 | 436,000 | 0 | 268,000 | |
| Loss on issuance of common stock | 0 | 0 | 231,000 | — | — | |
| Gain on debt conversion | −154,000 | 0 | 0 | — | — | |
| Gain on sales and disposals of property and equipment | −1,000 | −38,000 | −288,000 | 0 | 84,000 | |
| License and service receivable | 2 | −2 | 0 | — | — | |
| Unbilled receivable | 359,000 | −359,000 | 0 | — | — | |
| Prepaid expenses and other assets | −337,000 | 52,000 | 467,000 | 252,000 | 582,000 | |
| Accounts payable | −3 | −353,000 | 3 | 2 | −320,000 | |
| Accrued expenses | 167,000 | 285,000 | −2 | −1 | 535,000 | |
| Accrued interest | 609,000 | 509,000 | 48,000 | — | — | |
| Operating lease liabilities | −4,000 | −131,000 | −712,000 | −614,000 | −829,000 | |
| Net cash used in operating activities | −6 | −5 | −14 | −32 | −35 | |
| Proceeds from Sale of Other Property, Plant, and Equipment | 1,000 | 38,000 | 309,000 | — | — | |
| Net cash provided by investing activities | 1,000 | 38,000 | 309,000 | −66,000 | 2 | |
| Proceeds from the issuance of common stock, pre-funded warrants, and common stock warrants, net of issuance costs | 0 | 0 | 2 | — | — | |
| Proceeds from issuance of pre-funded warrants in connection with the 2025 PIPE transaction, net issuance costs | 10 | 0 | 0 | — | — | |
| Proceeds from debt financing obligation | 3 | 4 | 0 | 0 | 12 | |
| Repayment of term loan principal | −1 | −610,000 | −9 | 0 | −11 | |
| Proceeds (repayment) from advances from collaboration partners | −300,000 | 381,000 | 431,000 | 9 | 3 | |
| Net cash provided by (used in) financing activities | 11 | 3 | −4 | 9 | 51 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 5 | −1 | −18 | −23 | 18 | |
| Cash paid for interest | 25,000 | 139,000 | 989,000 | 1 | 728,000 | |
| Fair value of common stock and pre-funded warrants issued to loan holder | 0 | 865,000 | 0 | — | — | |
| Domicilium debt conversion, (principal of $7,366 and accrued interest of $1,131) | 8 | 0 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Eloxx Pharmaceuticals, Inc.'s CIK number?
Eloxx Pharmaceuticals, Inc.'s SEC CIK number is 0001035354 (1035354). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Eloxx Pharmaceuticals, Inc.'s SEC filings?
All of Eloxx Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Eloxx Pharmaceuticals, Inc. last report earnings?
Eloxx Pharmaceuticals, Inc. (ELOX) most recently filed an earnings 8-K with the SEC on Nov 13, 2023, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-23-117308). This is Eloxx Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Eloxx Pharmaceuticals, Inc.'s most recent earnings 8-K?
Eloxx Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed Nov 13, 2023 under accession 0001104659-23-117308. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Eloxx Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →